AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ProKidney Presents Two Abstracts at ASN's Kidney Week 2025, Including Phase 2 REGEN-007 Study Results
ByAinvest
Monday, Oct 20, 2025 7:32 am ET1min read
ProKidney Corp. announced two abstracts selected for presentation at the American Society of Nephrology's Kidney Week 2025. The late-breaking poster will present Phase 2 REGEN-007 study results on renal autologous cell therapy in diabetes and CKD, while another poster will discuss the cell-specific inflammatory profile characterization of the cell therapy candidate rilparencel. Both posters will be available on the company's website after the event.
ProKidney Corp. (Nasdaq: PROK), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced that it will present two posters at the upcoming American Society of Nephrology's (ASN) Kidney Week 2025 in Houston, Texas, from November 6 to 9, 2025. The presentations will highlight recent advancements in the company's cell therapy platform, specifically in the treatment of CKD.One of the presentations, a late-breaking poster, will report the Phase 2 REGEN-007 study results on "Renal Autologous Cell Therapy in Diabetes and CKD." This poster will be presented on November 6, 2025, from 10:00 AM to 12:00 PM CST, at Board #TH-PO1203, according to a . The study aims to evaluate the efficacy of autologous cell therapy in preserving kidney function for patients with diabetes and CKD.
The second poster, titled "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," will also be presented on November 6, 2025, from 10:00 AM to 12:00 PM CST, at Board #TH-PO0575, as noted in the Stocktitan announcement. This poster will discuss the inflammatory profile of the cell therapy candidate rilparencel, providing insights into its potential therapeutic effects and safety profile.
Both posters will be available on ProKidney's website after the event, providing further details and findings from the research presented at ASN Kidney Week 2025.
ProKidney's lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation. It is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes, according to a .
The company's focus on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient's own cells isolated for treatment positions ProKidney as a pioneer in the field. The company's REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant's own kidney tissue, as noted in the MarketScreener filing.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet